PARP1 and hepatocellular carcinoma: Compared with a single treatment of Olaparib, combination groups in HCC cell lines enhanced more growth inhibition, which indicated that combination with TRIP13 inhibitor DCZ0415 and PARP1 inhibitor Olaparib might be a potential therapy for HCC.